The present invention relates to a chimeric antigen receptor (CAR) which comprises an antigen-binding domain which selectively binds TCR beta constant region 1 (TRBC1) or TRBC2 cells such a T cells comprising such a CAR and the use of such cells for the treatment of a T-cell lymphoma or leukaemia in a subject.